A man with terminal heart disease is responding well three days after being given a genetically modified pig heart in a first-of-its-kind surgery, his doctors reported on Monday.
The surgery, performed by a team at the University of Maryland Medicine in the United States, is among the first to demonstrate the feasibility of a pig-to-human heart transplant, a field made possible by new gene editing tools.
If proven successful, scientists hope pig organs could help alleviate shortages of donor organs.
“We are proceeding cautiously, but we are also optimistic that this first-in-the-world surgery will provide an important new option for patients in the future,” Griffith added.
For David Bennett, a 57-year-old from Maryland, the heart transplant was his last option.
“It was either die or do this transplant. I want to live. I know it’s a shot in the dark, but it’s my last choice,” Bennett said a day before his surgery, according to a statement released by the university.
To move ahead with the experimental surgery, the university obtained emergency authorisation from the US Food and Drug Administration on New Year’s Eve through its compassionate use programme.
“The FDA used our data and data on the experimental pig to authorise the transplant in an end-stage heart disease patient who had no other treatment options,” said Dr Muhammad Mohiuddin, who heads the University’s programme on xenotransplantation – transplanting animal organs into humans.
About 110,000 Americans are currently waiting for an organ transplant, and more than 6,000 patients die each year before getting one, according to organdonor.gov.
Bennett’s genetically modified pig heart was provided by Revivicor, a regenerative medicine company based in Virginia. On the morning of the surgery, the transplant team removed the pig’s heart and placed it into a special device to preserve its function until the surgery.
Pigs have long been a tantalising source of potential transplants because their organs are so similar to humans.
Other organs from pigs being researched for transplantation into humans include kidneys, liver and lungs.
Prior efforts at pig-to-human transplants have failed because of genetic differences that caused organ rejection or viruses that posed an infection risk.
Scientists have tackled that problem by editing away potentially harmful genes.
In the heart implanted in Bennett, three genes previously linked with organ rejection were “knocked out” of the donor pig, and six human genes linked with immune acceptance were inserted into the pig genome.
Researchers also deleted a pig gene to prevent excessive growth of the pig heart tissue.
The work was funded in part with a $15.7 million research grant to evaluate Revivicor’s genetically-modified pig hearts in baboon studies.
In addition to the genetic changes to the pig heart, Bennett received an experimental anti-rejection drug.